Sennosides
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Sennosides: From Constipation (Laxative Use) to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Sennosides are stimulant laxatives (anthraquinone glycosides) that act on the colon. The TxGNN model predicts they may be effective for hypotrichosis simplex of the scalp, but no clinical trials and no publications currently support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the New Zealand licence records; the drug is a stimulant laxative |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 99.29% |
| Evidence Level | L5 |
| New Zealand Market Status | Cancelled only (no currently valid licence) |
| Number of Authorizations | 2 (both cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, sennosides are stimulant laxatives. Their active metabolite, rheinanthrone, acts on the colonic epithelium and enteric signalling, and they are poorly absorbed.
Hypotrichosis simplex of the scalp is a genetic hair follicle disorder (for example, variants in CDSN, APCDD1 or RPL21). No mechanistic link to sennosides was identified. The high TxGNN score appears to reflect proximity in the knowledge graph rather than a biologically plausible pathway.
The other top predictions show the same pattern: congenital hypotrichosis milia, diffuse alopecia areata, open-angle glaucoma, primary hereditary glaucoma and alopecia. Several are hair-related, which suggests a shared knowledge-graph artefact rather than independent biological signal. None has supporting trials or literature. This prediction should be treated as a computational hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 2712172 | Solax (cancelled) | Tab 50 mg with sennosides 8 mg | Not stated |
| 2069482 | Laxsol (cancelled) | Tab 50 mg with sennosides 8 mg | Not stated |
Safety Considerations
- Drug Interactions: No interaction records were found for this drug in the data compiled for this report.
- Other considerations: Chronic laxative use carries a risk of electrolyte disturbance, which would matter for any long-term repurposed use.
Please refer to the package insert for further safety information (warnings and contraindications).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has only model support (L5), with no clinical trials, no literature and no plausible mechanistic link. Sennosides have no currently valid New Zealand licence, and their action is local to the colon, so they are not expected to reach hair follicles.
To proceed, the following is needed:
- Mechanism of action data, to allow any meaningful mechanistic assessment
- Package insert warnings and contraindications from Medsafe
- Preclinical or mechanistic evidence linking sennosides or their metabolites to hair follicle biology
- Confirmation of the original approved indication and the route of administration that a new use would require
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.